Form 4: Abbott EVP Scoggins Sells Shares for Tax Obligations

Abbott Laboratories Executive Vice President Christopher J. Scoggins disposed of 4,997 common shares to cover tax liabilities at a price of $116.26 per share.

Summary

• Christopher J. Scoggins, Executive Vice President of Abbott Laboratories (ABT), reported a transaction involving the company's common shares.
• On February 27, 2026, Scoggins disposed of 4,997 common shares without par value.
• The shares were disposed of at a price of $116.26 per share.
• Following this transaction, Scoggins beneficially owns 77,126 common shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the share disposal is for tax purposes and not a discretionary sale indicating a change in management's outlook on the company's future performance.

Negatives

• The transaction resulted in a reduction of Christopher J. Scoggins' direct beneficial ownership in Abbott Laboratories by 4,997 shares.

Industry Context

StockSavvy.ai notes that routine tax-related sales by executives, often associated with the vesting of equity awards, are common practice across industries and typically do not signal a change in company fundamentals or management's outlook.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, which is generally considered a neutral event given the tax-related nature of the sale.

Key Dates

Recommendation

The reported transaction is a non-discretionary sale of shares to cover tax obligations, which is a common occurrence for executives. It does not reflect a change in the company's fundamentals or management's long-term view, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Abbott Laboratories, ABT, Insider Transaction, Form 4, Share Sale, Executive Compensation, Tax Withholding